News

In addition, QuatRx has also started dosing patients in a phase III clinical trial of ospemifene, the company’s product candidate for the treatment of post-menopausal vaginal atrophy, a

The initiation of phase I studies triggers a milestone payment of $2 million from Merck to Neurogen. The phase I clinical trial being conducted by Merck in Europe

A special protocol assessment (SPA) from the FDA specifies the phase III trial objective, design, clinical endpoints, and analyses needed to support regulatory approval. Under the terms of

The company said the results provide further evidence that its patented amino acid Controlled Delivery Technology (CDT) based platform may be a viable alternative to currently utilized solubility

The grant, provided by the Spinal Muscular Atrophy (SMA) Foundation, will fund activities by Columbia’s newly established Center for Motor Neuron Biology and Disease. It is a unique

Alliance UniChem has reached an agreement to acquire a 96% controlling stake in Russia’s A.P. Apteka Holding Ltd, for approximately GBP18 million. Apteka is Russia’s fifth largest pharmaceutical

The researchers found that Rad9, previously considered a “watchman” that checks for DNA damage, is actually a “repairman” that fixes dangerous breaks in the DNA double helix. They

Aloxi is a potent and long-lasting antiemetic belonging to the second generation of serotonin (5-HT3) antagonists, the leading class for the prevention of nausea and vomiting induced by

Biogen and Elan had voluntarily removed Tysabri from the US market and all ongoing clinical trials following reports of three patients developing a rare and potentially fatal brain